Borderline rpoB mutations transmit at the same rate as common rpoB mutations in a tuberculosis cohort in Bangladesh

The spread of multidrug-resistant tuberculosis (MDR-TB) is a growing problem in many countries worldwide. Resistance to one of the primary first-line drugs, rifampicin, is caused by mutations in the Mycobacterium tuberculosis rpoB gene. While some of these infrequent mutations show lower fitness in vitro than more common mutations, their in vivo fitness is currently unknown. We used a dataset of 394 whole genome sequenced MDR-TB isolates from Bangladesh, representing around 44% of notified MDR-TB cases over 6 years, to look at differences in transmission clustering between isolates with borderline rpoB mutations and those with common rpoB mutations. We found a relatively low percentage of transmission clustering in the dataset (34.8%) but no difference in clustering between different types of rpoB mutations. Compensatory mutations in rpoA, rpoB, and rpoC were associated with higher levels of transmission clustering as were lineages 2, 3, and 4 relative to lineage 1. Young people as well as patients with high sputum smear positive TB were more likely to be in a transmission cluster. Our findings show that although borderline rpoB mutations have lower in vitro growth potential this does not translate into lower transmission potential or in vivo fitness. Proper detection of these mutations is crucial to ensure they do not go unnoticed and spread MDR-TB within communities. Data summary WGS reads are available in the European Nucleotide Archive (PRJEB39569). In addition, WGS reads, as well as pDST and clinical data, are included in the ReSeqTB data platform and are accessible on registration at https://platform.reseqtb.org/. Custom scripts for clustering are available at https://github.com/conmeehan/pathophy.

[1]  T. Heupink,et al.  Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa , 2022, Microbial genomics.

[2]  Marc Choisy,et al.  Mycobacterium tuberculosis transmission in Birmingham, UK, 2009–19: An observational study , 2022, The Lancet regional health. Europe.

[3]  P. Cardona,et al.  The Origin and Maintenance of Tuberculosis Is Explained by the Induction of Smear-Negative Disease in the Paleolithic , 2022, Pathogens.

[4]  Md. Mojibur Rahman,et al.  Molecular Epidemiology and Genetic Diversity of Multidrug-Resistant Mycobacterium tuberculosis Isolates in Bangladesh , 2022, Microbiology spectrum.

[5]  Bangladesh Social Protection Public Expenditure Review , 2021 .

[6]  A. Kritski,et al.  Genomic-based surveillance reveals high ongoing transmission of multidrug-resistant Mycobacterium tuberculosis in Southern Brazil. , 2021, International journal of antimicrobial agents.

[7]  Sebastian M. Gygli,et al.  Prisons as ecological drivers of fitness-compensated multidrug-resistant Mycobacterium tuberculosis , 2021, Nature Medicine.

[8]  L. Rigouts,et al.  Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  Liliana K. Rutaihwa,et al.  HIV Coinfection Is Associated with Low-Fitness rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis , 2020, Antimicrobial Agents and Chemotherapy.

[10]  Q. Gao,et al.  Citywide Transmission of Multidrug-resistant Tuberculosis Under China’s Rapid Urbanization: A Retrospective Population-based Genomic Spatial Epidemiological Study , 2020 .

[11]  E. Schurr,et al.  The Interplay of Human and Mycobacterium Tuberculosis Genomic Variability , 2019, Front. Genet..

[12]  L. Rigouts,et al.  Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance , 2019, Scientific Reports.

[13]  D. Cirillo,et al.  Whole-Genome Sequencing of Drug-Resistant Mycobacterium tuberculosis Strains, Tunisia, 2012–2016 , 2019, Emerging infectious diseases.

[14]  D. Brites,et al.  The molecular clock of Mycobacterium tuberculosis , 2019, bioRxiv.

[15]  Jean-Charles Delvenne,et al.  Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study. , 2018, The Lancet. Infectious diseases.

[16]  Stefan Niemann,et al.  MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates , 2018, PeerJ.

[17]  Tanja Stadler,et al.  The relationship between transmission time and clustering methods in Mycobacterium tuberculosis epidemiology , 2018, bioRxiv.

[18]  M. Degano,et al.  Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis , 2018, Journal of Clinical Microbiology.

[19]  P. de Rijk,et al.  Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations , 2018, Scientific Reports.

[20]  S. Gagneux Ecology and evolution of Mycobacterium tuberculosis , 2018, Nature Reviews Microbiology.

[21]  K. Dooley,et al.  The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. , 2017, The Lancet. Respiratory medicine.

[22]  Qian Gao,et al.  Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. , 2017, The Lancet. Infectious diseases.

[23]  I. Comas Genomic Epidemiology of Tuberculosis. , 2017, Advances in experimental medicine and biology.

[24]  Marco Schito,et al.  Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Francesc Coll,et al.  Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences , 2015, Genome Medicine.

[26]  P. de Rijk,et al.  Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[27]  S. Gagneux,et al.  Consequences of genomic diversity in Mycobacterium tuberculosis. , 2014, Seminars in immunology.

[28]  A. Van Deun,et al.  Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[29]  D. Hughes,et al.  Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. , 2013, The Journal of antimicrobial chemotherapy.

[30]  L. Rigouts,et al.  Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard , 2013, Journal of Clinical Microbiology.

[31]  Marc Lipsitch,et al.  Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug resistant tuberculosis , 2013, Nature Genetics.

[32]  S. Gagneux Host–pathogen coevolution in human tuberculosis , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[33]  Stefan Niemann,et al.  Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes , 2011 .

[34]  A. Van Deun,et al.  Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. , 2010, American journal of respiratory and critical care medicine.

[35]  S. Borrell,et al.  Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[36]  C. Dye,et al.  Drivers of tuberculosis epidemics: the role of risk factors and social determinants. , 2009, Social science & medicine.

[37]  S. Gagneux Fitness cost of drug resistance in Mycobacterium tuberculosis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.